摘要
目的分析肿瘤抗血管生成靶向治疗疗效与安全性。方法回顾性分析,以2011年2月—2015年1月,医院肿瘤科收治的实体瘤恶性肿瘤患者作为研究对象,期间选择血管生成抑制剂治疗患者143例,纳入观察组,选择同期(性别一对一、年龄±2、同类型以及分期肿瘤、原发或复发)因非临床原因未联合血管生成抑制剂治疗的患者143例,纳入对照组。结果观察组缓解率53.1%高于对照组35.0%,差异有统计学意义(P<0.05)。观察组CR率、控制率分别为11.2%、90.2%,对照组7.0%、86.7%,差异无统计学意义(P>0.05),观察组12、24个月存活率分别为89.51%、71.33%,与对照组90.91%、66.43%,差异无统计学意义(P>0.05)。观察组无瘤生存时间11.5个月(4.6~28.5),高于对照组13.5个月(4.1~25.3),差异有统计学意义(P<0.05)。出现15例与血管生成抑制剂相关不良反应。结论肿瘤抗血管生成靶向治疗可能能增进肿瘤治疗效果,降低复发风险,但也存在不良反应。
Objective To analyze the curative effect and safety of tumor anti-angiogenesis. Methods 143 cases of solid malignant tumor patients treated with antagonist of vascular formation admitted and treated in our hospital from February 2011 to January 2015 were selected as the observation group, and 143 cases of patients(gender one-to-one, age ±2, the same type and staging tumors, primary and recurrent) without antagonist of vascular formation treatment due to the non-clinical factors were selected as the control group. Results The relief rate in the observation group was higher than that in the control group(53.1% vs 35.0%), and the difference was statistically significant(P<0.05), and the differences in the CR rate and control rate between the observation group and the control group were not statistically significant(11.2%,90.2%vs 7.0%,86.7%)(P>0.05), and the differences in the survival rates after 12 months and 24 months between the observation group and the control group were not statistically significant(89.51%,71.33% vs 90.91%,66.43%)(P >0.05), and the tumor-free survival time in the observation group was higher than that in the control group [11.5months(4.6-28.5) vs 13.5 months(4.1-25.3)], and the difference was statistically significant(P<0.05), and 15 cases were with adverse reactions related to the antagonist of vascular formation. Conclusion The targeted therapy of tumor anti-angiogenesis may enhance the tumor treatment effect and reduce the recurrent risks, but there are still adverse reactions.
出处
《系统医学》
2017年第10期133-135,共3页
Systems Medicine
关键词
肿瘤
抗血管生成
靶向治疗
Tumor
Anti-angiogenesis
Targeted therapy
